Last reviewed · How we verify
Separate administration — Competitive Intelligence Brief
phase 3
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
Separate administration (Separate administration) — Sanofi Pasteur, a Sanofi Company. This refers to a vaccination strategy where multiple vaccine components are administered at separate timepoints rather than as a combined formulation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Separate administration TARGET | Separate administration | Sanofi Pasteur, a Sanofi Company | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Separate administration CI watch — RSS
- Separate administration CI watch — Atom
- Separate administration CI watch — JSON
- Separate administration alone — RSS
Cite this brief
Drug Landscape (2026). Separate administration — Competitive Intelligence Brief. https://druglandscape.com/ci/separate-administration. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab